Skip to main content

Table 3 Treatment outcome by FCGR2A and FCGR3A genotypes, and therapy received

From: FCGR2A and FCGR3A polymorphisms and clinical outcome in metastatic colorectal cancer patients treated with first-line 5-fluorouracil/folinic acid and oxaliplatin +/- cetuximab

 

FLOX

FLOX + cetuximab

Interaction P-value

FCGR2A

H/H

H/R

R/R

H/H

H/R

R/R

 

Number of patients

N = 33

N = 90

N = 49

N = 81

N = 171

N = 80

 

Response (%)

58% (19/33)

41% (37/90)

31% (15/49)

43% (35/81)

49% (84/171)

53% (42/80)

0.03*

PFS, median (months)

8.4

7.9

7.5

8.3

7.8

7.6

0.35†

OS, median (months)

28.0

20.5

19.8

21.4

19.5

17.3

0.85†

FCGR3A

F/F

F/V

V/V

F/F

F/V

V/V

 

Number of patients

N = 79

N = 75

N = 15

N = 162

N = 131

N = 35

 

Response (%)

38% (30/79)

41% (31/75)

53% (8/15)

49% (79/162)

47% (62/131)

49% (17/35)

0.63*

PFS, median (months)

7.6

8.4

7.8

8.1

7.4

9.3

0.41†

OS, median (months)

20.4

20.5

19.7

19.7

21.1

20.1

0.78†

  1. *Logistic regression, †Cox proportional hazard model.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us